NZ596579A - Bace inhibitors - Google Patents

Bace inhibitors

Info

Publication number
NZ596579A
NZ596579A NZ596579A NZ59657910A NZ596579A NZ 596579 A NZ596579 A NZ 596579A NZ 596579 A NZ596579 A NZ 596579A NZ 59657910 A NZ59657910 A NZ 59657910A NZ 596579 A NZ596579 A NZ 596579A
Authority
NZ
New Zealand
Prior art keywords
bace inhibitors
compounds
disclosed
bace
inhibitors
Prior art date
Application number
NZ596579A
Other languages
English (en)
Inventor
Brian Morgan Watson
Leonard Larry Winneroski Jr
Grant Mathews Vaught
Chongsheng Eric Shi
James Edmund Audia
Dustin James Mergott
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ596579(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NZ596579A publication Critical patent/NZ596579A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/04—1,3-Thiazines; Hydrogenated 1,3-thiazines
    • C07D279/08—1,3-Thiazines; Hydrogenated 1,3-thiazines condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
NZ596579A 2009-07-09 2010-07-06 Bace inhibitors NZ596579A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22424109P 2009-07-09 2009-07-09
PCT/US2010/041034 WO2011005738A1 (fr) 2009-07-09 2010-07-06 Inhibiteurs de bace

Publications (1)

Publication Number Publication Date
NZ596579A true NZ596579A (en) 2013-12-20

Family

ID=42985394

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ596579A NZ596579A (en) 2009-07-09 2010-07-06 Bace inhibitors

Country Status (26)

Country Link
US (2) US8278441B2 (fr)
EP (1) EP2451793B1 (fr)
JP (1) JP5666578B2 (fr)
KR (1) KR101362557B1 (fr)
CN (1) CN102471296B (fr)
AR (1) AR077277A1 (fr)
AU (1) AU2010270691B8 (fr)
BR (1) BR112012000525A2 (fr)
CA (1) CA2764429C (fr)
CL (1) CL2012000033A1 (fr)
CO (1) CO6480979A2 (fr)
CR (1) CR20120011A (fr)
DO (1) DOP2012000004A (fr)
EA (1) EA019892B1 (fr)
EC (1) ECSP12011581A (fr)
HN (1) HN2012000012A (fr)
IL (1) IL216742A0 (fr)
MA (1) MA33492B1 (fr)
MX (1) MX2012000510A (fr)
NZ (1) NZ596579A (fr)
PE (1) PE20120632A1 (fr)
SG (1) SG177594A1 (fr)
TN (1) TN2011000673A1 (fr)
TW (1) TWI405765B (fr)
WO (1) WO2011005738A1 (fr)
ZA (1) ZA201109385B (fr)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
CN103936690B (zh) 2005-10-25 2016-06-08 盐野义制药株式会社 氨基二氢噻嗪衍生物
CA2683887A1 (fr) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Derives d'aminodihydrothiazine substitues par un groupe cyclique ayant une activite inhibitoire contre la production de proteine beta amyloide
EP2151435A4 (fr) 2007-04-24 2011-09-14 Shionogi & Co Composition pharmaceutique pour le traitement de la maladie d'alzheimer
UA101352C2 (uk) 2008-01-18 2013-03-25 Ейсей Р Енд Д Менеджмент Ко., Лтд. Конденсоване похідне амінодигідротіазину
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
EP2318416B1 (fr) * 2008-07-28 2013-09-04 Eisai R&D Management Co., Ltd. Derives de spiroaminodihydrothiazine
NZ591878A (en) * 2008-09-30 2012-06-29 Eisai R&D Man Co Ltd Novel fused aminodihydrothiazine derivative
US8703785B2 (en) * 2008-10-22 2014-04-22 Shionogi & Co., Ltd. 2-aminopyrimidin-4-one and 2-aminopyridine derivatives both having BACE1-inhibiting activity
GB0912778D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydro-oxazine derivatives
GB0912777D0 (en) 2009-07-22 2009-08-26 Eisai London Res Lab Ltd Fused aminodihydropyrimidone derivatives
WO2011044185A2 (fr) 2009-10-08 2011-04-14 Schering Corporation Composés hétérocycliques iminopentafluorosoufrés en tant qu'inhibiteurs de bace-1, compositions et leur utilisation
UA108363C2 (uk) 2009-10-08 2015-04-27 Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
EP2485591B1 (fr) 2009-10-08 2016-03-23 Merck Sharp & Dohme Corp. Composés de type dioxyde d'imino-thiadiazine utilisés en tant qu'inhibiteurs de bace, compositions en contenant et leur utilisation
US8557826B2 (en) 2009-10-08 2013-10-15 Merck Sharp & Dohme Corp. Pentafluorosulfur imino heterocyclic compounds as BACE-1 inhibitors, compositions, and their use
EP2511269A4 (fr) * 2009-12-11 2013-04-24 Shionogi & Co Composé hétérocyclique fusionné comportant un groupement amino
MX2012006491A (es) 2009-12-11 2012-07-03 Shionogi & Co Derivados de oxazina.
CN102933564B (zh) 2010-06-09 2015-07-22 詹森药业有限公司 用作β-分泌酶(BACE)抑制剂的5,6-二氢-2H-[1,4]噁嗪-3-基-胺衍生物
AU2011321427A1 (en) 2010-10-29 2013-05-02 Shionogi & Co., Ltd. Naphthyridine derivative
EP2634188A4 (fr) 2010-10-29 2014-05-07 Shionogi & Co Dérivé d'aminodihydropyrimidine fusionnée
BR112013015430A2 (pt) 2010-12-22 2016-09-20 Janssen Pharmaceutica Nv derivados de 5,6-diidro-imidazo[1,2-a]pirazin-8-ilamina úteis como inibidores de beta-secretase (bace)
GB201100181D0 (en) * 2011-01-06 2011-02-23 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101139D0 (en) 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
GB201101140D0 (en) * 2011-01-21 2011-03-09 Eisai Ltd Fused aminodihydrothiazine derivatives
MX2013005115A (es) 2011-01-21 2013-06-03 Eisai R&D Man Co Ltd Metodos y compuestos utiles en la sintesis de derivados de aminodihidrotiazina fusionados.
ES2534973T3 (es) 2011-03-09 2015-04-30 Janssen Pharmaceutica N.V. Derivados de 3,4-dihidro-pirrolo[1,2-a]pirazin-1-ilamina útiles como inhibidores de beta-secretasa (BACE)
US9145426B2 (en) 2011-04-07 2015-09-29 Merck Sharp & Dohme Corp. Pyrrolidine-fused thiadiazine dioxide compounds as BACE inhibitors, compositions, and their use
EP2694489B1 (fr) 2011-04-07 2017-09-06 Merck Sharp & Dohme Corp. Composés de dioxyde de thiadiazine condensés avec des dérivés oxacycliques en c5-c6 comme inhibiteurs de bace, compositions, et utilisation use
US8883779B2 (en) 2011-04-26 2014-11-11 Shinogi & Co., Ltd. Oxazine derivatives and a pharmaceutical composition for inhibiting BACE1 containing them
US8604024B2 (en) 2011-05-24 2013-12-10 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8598161B2 (en) 2011-05-24 2013-12-03 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
US8927535B2 (en) * 2011-07-06 2015-01-06 Hoffman-La Roche Inc. Cyclopropyl-fused-1,3-thiazepines as BACE1 and/or BACE2 inhibitors
KR20140054295A (ko) 2011-08-22 2014-05-08 머크 샤프 앤드 돔 코포레이션 Bace 억제제로서의 2-스피로-치환된 이미노티아진 및 그의 모노- 및 디옥시드, 조성물 및 그의 용도
EP2751116B1 (fr) 2011-08-31 2016-10-12 Pfizer Inc Hexahydropyrano[3,4-d][1,3]thiazine-2-amines
JO3143B1 (ar) 2012-04-03 2017-09-20 Lilly Co Eli مركبات تتراهيدرو بيرولو ثيازين
MX2014012683A (es) 2012-04-27 2015-01-16 Eisai R&D Man Co Ltd Metodo para producir el acido 5-(difluorometil)pirazin-2-carboxili co y un intermediario de la produccion de este.
WO2013164730A1 (fr) 2012-05-04 2013-11-07 Pfizer Inc. Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
GB201212871D0 (en) 2012-07-20 2012-09-05 Eisai Ltd Novel compounds
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014065434A1 (fr) 2012-10-24 2014-05-01 Shionogi & Co., Ltd. Dérivés de dihydrooxazine ou d'oxazépine ayant une activité inhibitrice de bace1
PT2912041T (pt) * 2012-10-26 2017-02-13 Lilly Co Eli Inibidores de bace
EP2931731A1 (fr) 2012-12-11 2015-10-21 Pfizer Inc. Composés d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
WO2014097038A1 (fr) 2012-12-19 2014-06-26 Pfizer Inc. Composés hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués carbocycliques et hétérocycliques
WO2014098831A1 (fr) 2012-12-19 2014-06-26 Bristol-Myers Squibb Company 4,6-diarylaminothiazines à titre d'inhibiteurs de bace1 et leur utilisation pour réduire la production des bêta-amyloïdes
WO2014120658A1 (fr) 2013-01-29 2014-08-07 Amgen Inc. Dérivés de 3-amino-5,6-dihydro-2h-1,4-thiazine multicycliques condensés et leur utilisation à titre d'inhibiteurs de bêta-sécrétase
CN104995176B (zh) 2013-02-12 2019-02-22 巴克老龄化研究所 调节bace所介导的app加工的乙内酰脲
CA2897678A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composes hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitues par un heteroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
EP2961749B1 (fr) 2013-03-01 2019-10-09 Amgen Inc. Composés perfluorés 5,6-dihydro-4h-1,3-oxazine-2-amine substitués en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation correspondants
CN105164121A (zh) 2013-03-08 2015-12-16 美国安进公司 作为β分泌酶抑制剂的全氟化环丙基稠合的1,3-噁嗪-2-胺化合物以及其使用方法
TWI593692B (zh) 2013-03-12 2017-08-01 美國禮來大藥廠 四氫吡咯并噻嗪化合物
JP6387402B2 (ja) 2013-06-12 2018-09-05 ヤンセン ファーマシューティカ エヌ．ベー． β−セクレターゼ（ＢＡＣＥ）の阻害剤としての４−アミノ−６−フェニル−５，６−ジヒドロイミダゾ［１，５−Ａ］ピラジン−３（２Ｈ）−オン誘導体
ES2721073T3 (es) 2013-06-12 2019-07-26 Janssen Pharmaceutica Nv Derivados de 4-amino-6-fenil-6,7-dihidro[1,2,3]triazolo[1,5 a]pirazina como inhibidores de beta-secretasa (BACE)
JO3318B1 (ar) 2013-06-18 2019-03-13 Lilly Co Eli مثبطات bace
WO2015017407A1 (fr) 2013-07-30 2015-02-05 Amgen Inc. Composés de dioxyde d'amino-thiazine bicycliques pontés en tant qu'inhibiteurs de bêta-sécrétase
PE20170327A1 (es) 2014-04-10 2017-04-21 Pfizer 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4d] [1,3] TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
US9550762B2 (en) 2014-08-08 2017-01-24 Amgen, Inc. Cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
CR20170187A (es) 2014-11-10 2018-02-01 H Lundbeck As 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer
MA40941A (fr) 2014-11-10 2017-09-19 H Lundbeck As 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1
JO3458B1 (ar) 2014-11-10 2020-07-05 H Lundbeck As 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1
WO2016096979A1 (fr) 2014-12-18 2016-06-23 Janssen Pharmaceutica Nv Composés fr 2,3,4,5-tétrahydropyridine-6-amine et 3,4-dihydro-2 h-pyrrol-5-amine inhibiteurs de la bêta-sécrétase
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
US9938266B2 (en) 2015-03-19 2018-04-10 Eli Lilly And Company Selective BACE1 inhibitors
AR104241A1 (es) 2015-04-29 2017-07-05 Lilly Co Eli Derivados de tetrahidrofuro tiazina como inhibidores de bace1 selectivos
US10246429B2 (en) 2015-08-06 2019-04-02 Amgen Inc. Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use
TW201717948A (zh) 2015-08-10 2017-06-01 Ｈ 朗德貝克公司 包括給予２－胺基－３，５，５－三氟－３，４，５，６－四氫吡啶的聯合治療
PE20181015A1 (es) 2015-08-12 2018-06-26 H Lundbeck As 2-amino-3-fluoro-3-(fluorometil)-6-meti-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
US20180230160A1 (en) * 2015-08-12 2018-08-16 H. Lundbeck A/S 2-amino-7a-phenyl-3,4,4a,5,7,7a-hexahydrofuro[3,4-b]pyridines as bace1 inhibitors
EP3353182A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc Dérivés de tétrahydropyrano[3,4-d][1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
WO2017051276A1 (fr) * 2015-09-24 2017-03-30 Pfizer Inc. N-[2-(2-amino-6,6-disubstitués-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl)-1,3-thiazol-4-yl]amides
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
TWI675034B (zh) * 2016-05-20 2019-10-21 美商美國禮來大藥廠 四氫呋喃并<img align="absmiddle" height="18px" width="27px" file="d10999.TIF" alt="其他非圖式 ed10999.png" img-content="tif" orientation="portrait" inline="yes" giffile="ed10999.png"></img>化合物及其作為選擇性ＢＡＣＥ１抑制劑之用途
CA3039586A1 (fr) 2016-11-04 2018-05-11 Janssen Pharmaceutica Nv Composes de 4,4 a, 5,7-tetrahydro -3 h-furo [3,4-b]pyridinyl
MX2019007102A (es) 2016-12-15 2019-12-16 Amgen Inc Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
ES2910367T3 (es) 2016-12-15 2022-05-12 Amgen Inc Derivados de tiazina y oxazina bicíclicos como inhibidores de beta-secretasa y métodos de uso
EP3555085B1 (fr) 2016-12-15 2020-12-02 Amgen Inc. Derivés thiazine fusionnés à un cyclopropyle utilisés en tant qu'inhibiteurs de la bêta-sécrétase et procédés d'utilisation
WO2018112094A1 (fr) 2016-12-15 2018-06-21 Amgen Inc. Dérivés de dioxyde de 1,4-thiazine et de dioxyde de 1,2,4-thiadiazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
MA52722A (fr) 2016-12-15 2021-04-14 Amgen Inc Dérivés d'oxazine en tant qu'inhibiteurs de bêta-sécrétase et procédés d'utilisation
CN110382506A (zh) * 2017-03-07 2019-10-25 詹森药业有限公司 β-分泌酶的抑制剂
MA47730A (fr) * 2017-03-07 2020-01-15 Janssen Pharmaceutica Nv Inhibiteurs de bêta-sécrétase
US20200010482A1 (en) * 2017-03-07 2020-01-09 Janssen Pharmaceutica Nv Inhibitors of beta secretase
EA201992076A1 (ru) * 2017-09-07 2020-03-19 Янссен Фармацевтика Нв Ингибиторы бета-секретазы
EA201992055A1 (ru) * 2017-09-07 2020-01-30 Янссен Фармацевтика Нв Ингибиторы бета-секретазы
EA201992108A1 (ru) * 2017-09-07 2020-01-27 Янссен Фармацевтика Нв Ингибиторы бета-секретазы
CN110590517A (zh) * 2019-09-24 2019-12-20 武汉嘉诺康医药技术有限公司 一种3，4-二羟基-2′-氯苯乙酮的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101061113A (zh) * 2004-11-23 2007-10-24 默克公司 作为β－内分泌抑制剂用于治疗阿耳茨海默氏病的2,3,4,6－四取代吡啶衍生物
CN103936690B (zh) * 2005-10-25 2016-06-08 盐野义制药株式会社 氨基二氢噻嗪衍生物
WO2007058581A1 (fr) * 2005-11-15 2007-05-24 Astrazeneca Ab Nouveaux derives de 2-aminopyrimidine derivatives et leur utilisation
EP2151435A4 (fr) * 2007-04-24 2011-09-14 Shionogi & Co Composition pharmaceutique pour le traitement de la maladie d'alzheimer
CA2683887A1 (fr) 2007-04-24 2008-11-06 Shionogi & Co., Ltd. Derives d'aminodihydrothiazine substitues par un groupe cyclique ayant une activite inhibitoire contre la production de proteine beta amyloide
ITTO20070665A1 (it) * 2007-09-24 2009-03-25 Rottapharm Spa Derivati amidinici, tioureici e guanidinici di 2-amminobenzotiazoli e amminobenzotiazine, nuovi agenti farmacologici per il trattamento delle patologie neurodegenerative.
UA101352C2 (uk) * 2008-01-18 2013-03-25 Ейсей Р Енд Д Менеджмент Ко., Лтд. Конденсоване похідне амінодигідротіазину
ES2738123T3 (es) 2008-06-13 2020-01-20 Shionogi & Co Derivado heterocíclico que contiene azufre que tiene actividad inhibitoria de ß-secretasa
NZ591878A (en) * 2008-09-30 2012-06-29 Eisai R&D Man Co Ltd Novel fused aminodihydrothiazine derivative

Also Published As

Publication number Publication date
TW201113289A (en) 2011-04-16
AU2010270691B2 (en) 2013-08-01
SG177594A1 (en) 2012-02-28
PE20120632A1 (es) 2012-05-26
EP2451793B1 (fr) 2016-11-02
CA2764429C (fr) 2014-11-18
HN2012000012A (es) 2014-05-26
US8278441B2 (en) 2012-10-02
CN102471296B (zh) 2014-11-12
CL2012000033A1 (es) 2012-09-14
EP2451793A1 (fr) 2012-05-16
AU2010270691A1 (en) 2011-12-22
AR077277A1 (es) 2011-08-17
KR20120027482A (ko) 2012-03-21
MX2012000510A (es) 2012-01-27
WO2011005738A1 (fr) 2011-01-13
US20120323001A1 (en) 2012-12-20
DOP2012000004A (es) 2012-01-31
JP2012532874A (ja) 2012-12-20
KR101362557B1 (ko) 2014-02-13
CO6480979A2 (es) 2012-07-16
CN102471296A (zh) 2012-05-23
JP5666578B2 (ja) 2015-02-12
TN2011000673A1 (en) 2013-05-24
AU2010270691B8 (en) 2013-11-28
MA33492B1 (fr) 2012-08-01
US20110009395A1 (en) 2011-01-13
ZA201109385B (en) 2013-05-29
TWI405765B (zh) 2013-08-21
EA201270149A1 (ru) 2012-06-29
ECSP12011581A (es) 2012-02-29
BR112012000525A2 (pt) 2015-09-15
CA2764429A1 (fr) 2011-01-13
EA019892B1 (ru) 2014-07-30
IL216742A0 (en) 2012-03-01
CR20120011A (es) 2012-02-09

Similar Documents

Publication Publication Date Title
NZ596579A (en) Bace inhibitors
MX2007011023A (es) 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3.
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
UA103272C2 (uk) 2-аміно-5,5-дифтор-5,6-дигідро-4h-оксазини як інгібітори bace1 і/або bace2
EP1841426A4 (fr) Carbinamines tertiaires incluant des heterocycles substitues, agissant en tant qu&#39;inhibiteurs de la beta-secretase et utilisees dans le traitement de la maladie d&#39;alzheimer
TW200728305A (en) Spiropiperidine beta-sectetase inhibitors for the treatment of alzheimer&#39;s disease
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
EA200801998A1 (ru) ПИРИДИН[3,4-b]ПИРАЗИНОНЫ
WO2008030412A3 (fr) Inhibiteurs de la spiropipéridine bêta-sécrétase pour le traitement de la maladie d&#39;alzheimer
TW200745004A (en) Novel compounds, their preparation and use
TW200734311A (en) New compounds
EP2091328A4 (fr) Composés de spiropipéridine inhibiteurs de la bêta-sécrétase pour le traitement de la maladie d&#39;alzheimer
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
EA200801481A1 (ru) 5-(арилсульфонил)пиразолопиперидины
ES2368594T3 (es) Derivados sustituidos de ciclohexilmetilo.
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
MX2007007103A (es) Derivados espiro como inhibidores de lipoxigenasa.
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
EP1817312A4 (fr) Inhibiteurs de l&#39;aminopyridyle de la beta-secretase macrocyclique permettant de traiter la maladie d&#39;alzheimer
WO2006055434A3 (fr) Inhibiteurs de la beta-secretase formes d&#39;amines tertiaires macrocycliques pour le traitement de la maladie d&#39;alzheimer
EP1951709A4 (fr) Composes d imidazolidinone utiles en tant qu inhibiteurs de la beta-secretase lors du traitement de la maladie d alzheimer
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
TW200637817A (en) 5-aminoindole derivatives
PH12014502541A1 (en) 5-amino [1,4] thiazines as bace 1 inhibitors
DE602006005640D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate als arzneimittel zur behandlung von unfruchtbarkeit

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 06 JUL 2017 BY THOMSON REUTERS

Effective date: 20140619

LAPS Patent lapsed